Guillaume Lessene

Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.

Zilu Wang, Huimin Hu, Luuk Heitink, Kelly Rogers, Yue You, Tao Tan, Connie Li Wai Suen, Alex Garnham, Hao Chen, Elizabeth Lieschke, Sarah T Diepstraten, Catherine Chang, Tianwei Chen, Diane Moujalled, Kate Sutherland, Guillaume Lessene, Oliver M Sieber, Jane Visvader, Gemma L Kelly, Andreas Strasser

Journal article  |  2023  |  Cell Death Differ

The original version of this article contained a mistake. When preparing the revised version of this paper the authors omitted a n..

From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors

Christopher R Gardner, Katherine A Davies, Ying Zhang, Martin Brzozowski, Peter E Czabotar, James M Murphy, Guillaume Lessene

Journal article  |  2023  |  JOURNAL OF MEDICINAL CHEMISTRY

Necroptosis is a regulated caspase-independent form of necrotic cell death that results in an inflammatory phenotype. This process..

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.

Donia M Moujalled, Fiona C Brown, Chong Chyn Chua, Michael A Dengler, Giovanna Pomilio, Natasha S Anstee, Veronique Litalien, Ella Thompson, Thomas Morley, Sarah MacRaild, Ing S Tiong, Rhiannon Morris, Karen Dun, Adrian Zordan, Jaynish Shah, Sebastien Banquet, Ensar Halilovic, Erick Morris, Marco J Herold, Guillaume Lessene, et al.

Journal article  |  2023  |  Blood

Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined w..

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells

Zilu Wang, Huimin Hu, Luuk Heitink, Kelly Rogers, Yue You, Tao Tan, Connie Li Wai Suen, Alex Garnham, Hao Chen, Elizabeth Lieschke, Sarah TT Diepstraten, Catherine Chang, Diane Moujalled, Kate Sutherland, Guillaume Lessene, Oliver MM Sieber, Jane Visvader, Gemma LL Kelly, Andreas Strasser

Journal article  |  2023  |  CELL DEATH AND DIFFERENTIATION

Mutant TP53 proteins are thought to drive the development and sustained expansion of cancers at least in part through the loss of ..

Dual drug targeting to kill colon cancers.

Silvia Paola Corona, Francesca Walker, Janet Weinstock, Guillaume Lessene, Maree Faux, Antony W Burgess

Journal article  |  2022  |  Cancer Med

INTRODUCTION: Colorectal cancer (CRC) is driven by a small set of oncogenic and tumour suppressor mutations. However, different co..

Development of NanoLuc-targeting protein degraders and a universal reporter system to benchmark tag-targeted degradation platforms

Christoph Grohmann, Charlene M Magtoto, Joel R Walker, Ngee Kiat Chua, Anna Gabrielyan, Mary Hall, Simon A Cobbold, Stephen Mieruszynski, Martin Brzozowski, Daniel S Simpson, Hao Dong, Bridget Dorizzi, Annette Jacobsen, Emma Morrish, Natasha Silke, James M Murphy, Joan K Heath, Andrea Testa, Chiara Maniaci, Alessio Ciulli, et al.

Journal article  |  2022  |  NATURE COMMUNICATIONS

Modulation of protein abundance using tag-Targeted Protein Degrader (tTPD) systems targeting FKBP12F36V (dTAGs) or HaloTag7 (HaloP..

Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors

Dale J Calleja, Nathan Kuchel, Bernadine GC Lu, Richard W Birkinshaw, Theresa Klemm, Marcel Doerflinger, James P Cooney, Liana Mackiewicz, Amanda E Au, Yu Q Yap, Timothy R Blackmore, Kasiram Katneni, Elly Crighton, Janet Newman, Kate E Jarman, Melissa J Call, Bernhard C Lechtenberg, Peter E Czabotar, Marc Pellegrini, Susan A Charman, et al.

Journal article  |  2022  |  FRONTIERS IN CHEMISTRY

The COVID-19 pandemic continues unabated, emphasizing the need for additional antiviral treatment options to prevent hospitalizati..

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

Lahiru Gangoda, Robyn L Schenk, Lin Tai, Pacman Szeto, Jen G Cheung, Andreas Strasser, Guillaume Lessene, Mark Shackleton, Marco J Herold

Journal article  |  2022  |  CELL DEATH & DISEASE

The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL

Annette Jacobsen, Catia L Pierotti, Kym N Lowes, Amanda E Au, Ying Zhang, Nima Etemadi, Cheree Fitzgibbon, Wilhelmus JA Kersten, Andre L Samson, Mark F van Delft, David CS Huang, Helene Jousset Sabroux, Guillaume Lessene, John Silke, James M Murphy

Journal article  |  2022  |  CELL DEATH & DISEASE

Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed line..

BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells

Diane Moujalled, Adam G Southon, Eiman Saleh, Kerstin Brinkmann, Francine Ke, Melinda Iliopoulos, Ryan S Cross, Misty R Jenkins, Duong Nhu, Zilu Wang, Melissa X Shi, Ruth M Kluck, Guillaume Lessene, Stephanie Grabow, Ashley Bush, Andreas Strasser

Journal article  |  2022  |  CELL DEATH AND DIFFERENTIATION

Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer, with treatment options often constrained due..